Project Number: 8042-32000-107-30-T
Project Type: Trust Fund Cooperative Agreement
Start Date: Oct 1, 2017
End Date: Dec 30, 2019
Investigate effects of commercial Seppic oral adjuvants on recombinant protein vaccination against avian coccidiosis. Underling protective mechanisms that are associated with recombinant vaccination with oral adjuvants will be investigated.
ARS will test vaccine efficacy of recombinant coccidian proteins that ARS produced with commercially available Seppic adjuvants using ARS-established in vivo coccidiosis disease challenge model. Challenge model will be evaluated using established clinical criteria for coccidiosis infection.